CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
hu3S193biological
Likely dose
hu3S193 20 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00617773
NCT00617773Phase 2Completed
CompareCT.gov

A PHASE II TRIAL OF Hu3S193 THERAPY FOR PATIENTS WITH PLATINUM REFRACTORY OR PLATINUM RESISTANT EPITHELIAL OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER

Recepta Biopharma·interventional·Posted Feb 18, 2008·Updated Nov 26, 2013

In Brief

A Phase 2 clinical trial evaluating hu3S193 for Fallopian Tube Cancer and 2 related conditions. Completed, enrolled 31 participants across 8 sites.

Detailed Summary

RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well Hu3S193 works in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cavity cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
CountriesBrazil
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 18, 2008
Enrollment StartMay 1, 2008
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 18.4 years ago

Interventions

hu3S193biological

20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)